Price Alert

Pacira BioSciences Inc. (PCRX)

NASDAQ: PCRX · Real-Time Price · USD

26.73

-0.45 (-1.66%)

At close: Sep 04, 2025, 3:59 PM

26.73

0.00%

After-hours: Sep 04, 2025, 04:10 PM EDT

Pacira BioSciences Statistics

Share Statistics

Pacira BioSciences has 44.93M shares outstanding. The number of shares has increased by 0.39% in one year.

Shares Outstanding	44.93M
Shares Change (YoY)	0.39%
Shares Change (QoQ)	0.06%
Owned by Institutions (%)	99.99%
Shares Floating	42.79M
Failed to Deliver (FTD) Shares	572
FTD / Avg. Volume	0.09%

Short Selling Information

The latest short interest is 6.29M, so 14% of the outstanding shares have been sold short.

Short Interest	6.29M
Short % of Shares Out	14%
Short % of Float	20.07%
Short Ratio (days to cover)	6.44

Valuation Ratios

The PE ratio is -8.75 and the forward PE ratio is 8.35. Pacira BioSciences's PEG ratio is 0.03.

PE Ratio	-8.75
Forward PE	8.35
PS Ratio	1.24
Forward PS	1.5
PB Ratio	1.12
P/FCF Ratio	4.87
PEG Ratio	0.03

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Pacira BioSciences.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.82.

Current Ratio	2.4
Quick Ratio	2
Debt / Equity	0.82
Debt / EBITDA	21.94
Debt / FCF	3.57
Interest Coverage	-4.43

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$889.55K
Profits Per Employee	$-126.35K
Employee Count	788
Asset Turnover	0.45
Inventory Turnover	1.36

Taxes

Income Tax	36.45M
Effective Tax Rate	-57.77%

Stock Price Statistics

The stock price has increased by 79.52% in the last 52 weeks. The beta is 0.48, so Pacira BioSciences's price volatility has been higher than the market average.

Beta	0.48
52-Week Price Change	79.52%
50-Day Moving Average	23.82
200-Day Moving Average	23.38
Relative Strength Index (RSI)	70.35
Average Volume (20 Days)	652,364

Income Statement

In the last 12 months, Pacira BioSciences had revenue of 700.97M and earned -99.56M in profits. Earnings per share was -2.15.

Revenue	700.97M
Gross Profit	530.54M
Operating Income	-73.37M
Net Income	-99.56M
EBITDA	29.12M
EBIT	-49.67M
Earnings Per Share (EPS)	-2.15

Full Income Statement

Balance Sheet

The company has 276.77M in cash and 638.85M in debt, giving a net cash position of -362.08M.

Cash & Cash Equivalents	276.77M
Total Debt	638.85M
Net Cash	-362.08M
Retained Earnings	-206.36M
Total Assets	1.54B
Working Capital	432.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 189.39M and capital expenditures -10.64M, giving a free cash flow of 178.75M.

Operating Cash Flow	189.39M
Capital Expenditures	-10.64M
Free Cash Flow	178.75M
FCF Per Share	3.87

Full Cash Flow Statement

Margins

Gross margin is 75.69%, with operating and profit margins of -10.47% and -14.2%.

Gross Margin	75.69%
Operating Margin	-10.47%
Pretax Margin	-9%
Profit Margin	-14.2%
EBITDA Margin	4.15%
EBIT Margin	-10.47%
FCF Margin	25.5%

Dividends & Yields

PCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for PCRX is $24, which is -11.7% lower than the current price. The consensus rating is "Buy".

Price Target	$24
Price Target Difference	-11.7%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.29
Piotroski F-Score	6